BELL-ID
18.2.2016 02:01:04 CET | Business Wire | Press release
Bell ID, the mobile payments specialist recently acquired by Rambus Cryptography Research, today announces it will support international issuing banks, payment schemes and processors to integrate with Android Pay. Bell ID customers can utilize its Token Service Provider (TSP) software to enable and secure near field communication (NFC) payments functionality on Android phones.
Android Pay is a mobile payment solution that offers people simplicity and security when paying for things with their Android devices. Bell ID’s TSP technology will secure Android Pay transactions via tokenization*.
"Mobile payments is a big priority for Google and we're working to support a wide range of issuers to make Android Pay available to everyone," says Pali Bhat, Senior Director, Product Management, Google, "Bell ID's integration takes us one step further in this direction.”
“A lot of our customers are keen to integrate with Android Pay and this support enables us to answer this demand,” adds Dr. Martin Scott, senior vice president and general manager of the Rambus Cryptography Research division. “With this relationship in place, Bell ID is now one of the few solution providers that can help banks to reach their full customer base, regardless of the smartphone they own. Bell ID does this by supporting the vast majority of OEM wallet, mobile operating system and secure element combinations. 2016 is going to be the biggest year yet and we're excited to be supporting the future of payments.”
Bell ID offers one software platform for issuing banks, processors and payment schemes to support mobile NFC payments. EMV® card credentials can be loaded and managed on a mobile device or in the cloud, using host card emulation (HCE). The solution is backed by a comprehensive EMVCo tokenization module that removes vulnerable card data from the payment network.
Visit the Bell ID website to learn more about Token Service Provider or Android Pay integration. Bell ID will also be present at Mobile World Congress with its virtual reality demonstration of the tokenization process associated with a mobile payment http://www.bellid.com/company/events/ .
For further media information, please contact Rob Peryer or David Amos at iseepr: rob@iseepr.co.uk / david@iseepr.co.uk or on + 44 (0) 1943 468007
Notes to editors
* Tokenization secures your payment credentials by replacing them with a randomly generated number which resembles the customer’s primary account number (PAN). This unique identifier, called a ‘payment token’ or ‘tokenized PAN’, is worthless if stolen as it essentially acts as a reference for a consumer’s original card data which only the card networks and/or the consumer’s bank can map back to the original account.
About Bell ID
Banks, governments and enterprises worldwide rely on Bell ID solutions to safely issue and manage credentials on many millions of smartcards, smartphones and connected devices. The Bell ID software solutions integrate with any third party technology and simplify the issuing complexities of payment, identity, loyalty and transit applications. Whether it’s EMV payments data stored on a chip card, in an NFC-enabled mobile device or in the cloud leveraging HCE, Bell ID has the expertise to manage the lifecycle of any application on any form factor. These award winning solutions meet the demanding requirements of international standardization bodies and payment networks.
In January 2016, Bell ID was acquired by Rambus (NASDAQ:RMBS) Cryptography Research and has a strong presence across the globe with operations in Europe, North America, Australia, the Middle East and Africa. Bell ID maintains one of the largest teams worldwide dedicated to credential lifecycle management.
For more information, please visit www.bellid.com or follow us on LinkedIn and Twitter .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160217006638/en/
Contact:
iseepr
Rob Peryer, + 44 (0) 1943 468007
rob@iseepr.co.uk
David
Amos, + 44 (0) 1943 468007
david@iseepr.co.uk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom